Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion
作者： Bin Peng , Catherine Dutreix , Gunther Mehring , Michael J. Hayes , Monique Ben-Am
关键词: Capsule 、 Intestinal absorption 、 Crossover study 、 Half-life 、 Bioavailability 、 Imatinib 、 Medicine 、 Imatinib mesylate 、 Pharmacology 、 Pharmacokinetics
摘要: The purpose of this study was to investigate the absolute bioavailability a single oral dose imatinib (Glivec), 400 mg (capsules vs. solution), compared with imatinib, 100 (intravenous [i.v.] infusion), in healthy subjects. Twelve subjects received treatment each period: 400-mg capsule form or as solution 100-mg i.v. infusion imatinib. Plasma concentrations were measured following treatment; pharmacokinetic parameters and determined. Absolute values (compared infusion) for 98.3% 97.2%, respectively. Both rate extent absorption, by C(max), partial AUC, total similar intended market. solution, completely absorbed almost bioavailable (> 97%).
sci-hub.se 参考文章(16)
Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, Moshe Talpaz, Brian Druker, None, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia The New England Journal of Medicine. ,vol. 346, pp. 645- 652 ,(2002) , 10.1056/NEJMOA011573
Brian P. Rubin, Scott M. Schuetze, Janet F. Eary, Thomas H. Norwood, Sohail Mirza, Ernest U. Conrad, James D. Bruckner, Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. Journal of Clinical Oncology. ,vol. 20, pp. 3586- 3591 ,(2002) , 10.1200/JCO.2002.01.027
Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561
R. Bakhtiar, L. Khemani, M. Hayes, T. Bedman, F. Tse, Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. ,vol. 28, pp. 1183- 1194 ,(2002) , 10.1016/S0731-7085(02)00080-8
Stephen G O'Brien, François Guilhot, Richard A Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes, Klaus Lechner, Johan L Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John Shepherd, Bengt Simonsson, Alois Gratwohl, John M Goldman, Hagop Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E Bolton, Renaud Capdeville, Brian J Druker, None, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia The New England Journal of Medicine. ,vol. 348, pp. 994- 1004 ,(2003) , 10.1056/NEJMOA022457
Karl Peggs, Stephen Mackinnon, Imatinib Mesylate — The New Gold Standard for Treatment of Chronic Myeloid Leukemia New England Journal of Medicine. ,vol. 348, pp. 1048- 1050 ,(2003) , 10.1056/NEJME030009
T. Lugo, A. Pendergast, A. Muller, O. Witte, Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. ,vol. 247, pp. 1079- 1082 ,(1990) , 10.1126/SCIENCE.2408149
Grant R. Wilkinson, Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans Journal of Pharmacokinetics and Biopharmaceutics. ,vol. 24, pp. 475- 490 ,(1996) , 10.1007/BF02353475
Thomas N. Tozer, Malcolm Rowland, Clinical pharmacokinetics : concepts and applications 神戸学院大学薬学部紀要. ,vol. 3, pp. 1- 15 ,(1989)
Paola Dal Cin, Carl-Henrik Heldin, Jan P. Dumanski, Arne Östman, Tobias Sjöblom, Elisabeth Buchdunger, Kevin P. O’Brien, Kristian Pietras, Akira Shimizu, Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Research. ,vol. 61, pp. 5778- 5783 ,(2001)